Influenza PR8 HA-specific Fab fragments produced by phage display methods.

Influenza PR8 HA-specific Fab fragments produced by phage display methods. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Influenza PR8 HA-specific Fab fragments produced by phage display methods. Abstract Text:

Hideki Asanuma,Ayano Matsumoto-Takasaki,Yujiro Suzuki,Shin-Ichi Tamura,Tetsutaro Sata,Yu Kusada,Misao Matsushita,Yoko Fujita-Yamaguchi,Hideki Asanuma,Ayano Matsumoto-Takasaki,Yujiro Suzuki,Shin-Ichi Tamura,Tetsutaro Sata,Yu Kusada,Misao Matsushita,Yoko Fujita-Yamaguchi,Hideki Asanuma,Ayano Matsumoto-Takasaki,Yujiro Suzuki,Shin-Ichi Tamura,Tetsutaro Sata,Yu Kusada,Misao Matsushita,Yoko Fujita-Yamaguchi,

Anti-influenza hemagglutinin (HA) Fabs were isolated from a phage display library using purified HA of influenza virus A/Puerto Rico/8/34 (PR8; H1N1) as an antigen. Four Fab clones displaying a 25-50-fold higher binding signal to PR8 HA than the control were selected for further analysis and comparison with anti-PR8 monoclonal antibody (mAb). All four Fabs and mAb recognized the PR8 HA under non-reducing conditions but rarely bound to reduced PR8 HA. Inhibition of influenza virus infection on MDCK cells was observed with Fab1 and mAb in a dose-dependent manner while Fab3 and 4 exhibited only a partial inhibitory effect. Moreover, Fab1 clone and mAb exhibited cross-reactivity with the A/Peking/262/95 (A/Peking; H1N1) strain. The inhibitory effects of mAb on both influenza strains were more potent than Fab1, which is likely attributed to its higher affinity for the antigen. SPR analyses, in fact, revealed that Fab1 and mAb have K(D) of 1.5x10(-8) and 3.2x10(-9)M, respectively. These results strongly suggest that phage library-derived Fabs can be readily prepared and that such HA-specific Fabs with inhibitory action on influenza infection may be used to treat influenza patients.

Influenza PR8 HA-specific Fab fragments produced by phage display methods. Publishing Authors By Initials

H Asanuma,A Matsumoto-Takasaki,Y Suzuki,S Tamura,T Sata,Y Kusada,M Matsushita,Y Fujita-Yamaguchi,H Asanuma,A Matsumoto-Takasaki,Y Suzuki,S Tamura,T Sata,Y Kusada,M Matsushita,Y Fujita-Yamaguchi,H Asanuma,A Matsumoto-Takasaki,Y Suzuki,S Tamura,T Sata,Y Kusada,M Matsushita,Y Fujita-Yamaguchi,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Influenza PR8 HA-specific Fab fragments produced by phage display methods. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Biochemical and biophysical research communication

VOLUME: 366

Page Numbers: 445-9

Journal Abbreviation: Biochem. Biophys. Res. Commun.

ISSN: 1090-2104

DAY: 5

MONTH: 12

YEAR: 2007

Influenza PR8 HA-specific Fab fragments produced by phage display methods. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 372516

Influenza PR8 HA-specific Fab fragments produced by phage display methods. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Influenza PR8 HA-specific Fab fragments produced by phage display methods. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Influenza PR8 HA-specific Fab fragments produced by phage display methods.

AFFILIATION: Department of Applied Biochemistry, School of Engineering, Tokai University, 1117 Kitakaname, Hiratsuka-shi, Kanagawa 259-1292, Japan; CREST, Japan Science and Technology Agency (JST), Japan.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Biochem Biophys Res Commun

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Influenza PR8 HA-specific Fab fragments produced by phage display methods Related Publications

• Influenza PR8 HA-specific Fab fragments produced by phage display methods.
• Isolation and characterization of phage-displayed single chain antibodies recognizing nonreducing terminal mannose residues. 1. A new strategy for generation of anti-carbohydrate antibodies.
• Isolation and characterization of phage-displayed single chain antibodies recognizing nonreducing terminal mannose residues. 2. Expression, purification, and characterization of recombinant single chain antibodies.